Clinical Trials/2023-505204-34-00

2023-505204-34-00RecruitingPhase 1

Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies

Schrodinger Inc.18 sites in 5 countries22 target enrollmentStarted: September 27, 2023Last updated: January 9, 2025

Trial Snapshot

Phase: Phase 1
Status: Recruiting
Sponsor: Schrodinger Inc.
Enrollment: 22
Locations: 18

Study Overview Eligibility Criteria Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages: 18 years to 65+ years (65+ Years, 18-64 Years)
Accepts Healthy Volunteers: No

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Investigators

Sponsor

Schrodinger Inc.

Sponsor Class

Pharmaceutical company

Responsible Party

Principal Investigator

Principal Investigator

Karine Cadren

Scientific

Schrodinger Inc.

Study Sites (18)

Loading locations...

Similar Trials

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

NCT07260305Kangabio AUSTRALIA LTD PTY57

TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors

NCT07266298Neowise Biotechnology24

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)

NCT07260812TCRx Therapeutics Co.Ltd18

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung Cancer

NCT07261631Novartis Pharmaceuticals180

Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC)

2023-504963-17-00Merck Sharp & Dohme LLC76

Phase 1, open-label, multicenter, dose... | Clinical Trial